Fiche publication
Date publication
janvier 2022
Journal
European journal of pain (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr YALCIN CHRISTMANN Ipek
,
Dr BARROT Michel
Tous les auteurs :
Bohren Y, Timbolschi DI, Muller A, Barrot M, Yalcin I, Salvat E
Lien Pubmed
Résumé
Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory system. A number of preclinical studies have provided evidence for the involvement of cytokines, predominantly secreted by a variety of immune cells and by glial cells from the nervous system, in neuropathic pain conditions. Clinical trials and the use of anti-cytokine drugs in different neuropathic aetiologies support the relevance of cytokines as treatment targets. However, the use of such drugs, in particularly biotherapies, can provoke notable adverse effects. Moreover, it is challenging to select one given cytokine as a target, among the various neuropathic pain conditions. It could thus be of interest to target other proteins, such as growth factors, in order to act more widely on the neuroinflammation network. Thus, platelet-rich plasma (PRP), an autologous blood concentrate, is known to contain a natural concentration of growth factors and immune system messengers and is widely used in the clinical setting for tissue regeneration and repair.
Mots clés
Animals, Cytokines, metabolism, Humans, Intercellular Signaling Peptides and Proteins, therapeutic use, Neuralgia, drug therapy, Neuroglia, metabolism, Platelet-Rich Plasma, metabolism
Référence
Eur J Pain. 2022 01;26(1):43-60
